Boehringer Ingelheim
Clinical trials sponsored by Boehringer Ingelheim, explained in plain language.
-
Hope for rare skin disease: new drug trial shows promise
Disease control TerminatedThis study tested a medicine called spesolimab in people aged 12 and older with Netherton syndrome, a rare genetic skin condition causing redness and scaling. Participants received either spesolimab or a placebo injection, with the placebo group switching to the real drug after 4…
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 28, 2026 23:52 UTC
-
Heart attack drug trial halted early – what we know
Disease control TerminatedThis study looked at whether a single dose of the experimental drug BI 765845 could help people who recently had a heart attack. About 160 adults were randomly assigned to receive the drug or a placebo, and their heart health was tracked for 3 months. The study was terminated ear…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Healthy men needed for drug metabolism study – no treatment benefit
Knowledge-focused TerminatedThis early-stage study looked at how healthy men absorb, break down, and eliminate the experimental drug BI 1819479. The trial was stopped early and involved only 7 participants. It was not designed to treat any disease, but to gather basic information about the drug's behavior i…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Apr 28, 2026 23:50 UTC
-
Healthy men help scientists understand new drug's journey through the body
Knowledge-focused TerminatedThis early-stage study looked at how healthy men absorb, break down, and get rid of an experimental drug called BI 1839100. The goal was to measure how much of the drug reaches the bloodstream and how it leaves the body in urine and stool. The study was stopped early, but the inf…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Apr 26, 2026 20:00 UTC